A survey of across-target bioactivity results of small molecules in PubChem

Bioinformatics

Volumn 25, Issue 17, 2009, Pages 2251-2255

  Han, Lianyi ^a   Wang, Yanli ^a   Bryant, Stephen H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOASSAY; DATA MINING; DRUG RESEARCH; DRUG TARGETING; HIGH THROUGHPUT SCREENING; INFORMATION PROCESSING; PRIORITY JOURNAL; PROTEIN DATABASE; PROTEIN INTERACTION; PROTEIN TARGETING; SEQUENCE HOMOLOGY;

CLUSTER ANALYSIS; DATA COLLECTION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; SMALL MOLECULE LIBRARIES;

EID: 69949134994     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btp380     Document Type: Article

References (20)

1. Altschul,S.F. et al. (1997) Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402.
2. Austin,C.P. et al. (2004) NIH Molecular Libraries Initiative. Science, 306, 1138-1139.
3. Azzaoui,K. et al. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. Chem. Med. Chem., 2, 874-880.
4. Burbaum,J.J. and Sigal,N.H. (1997) New technologies for high-throughput screening. Curr. Opin. Chem. Biol., 1, 72-78.
5. Feng,B.Y. et al. (2008) Small-molecule aggregates inhibit amyloid polymerization. Nat. Chem. Biol., 4, 197-199.
6. Gribbon,P. and Sewing,A. (2005) High-throughput drug discovery: What can we expect from HTS? Drug Discov. Today, 10, 17-22.
7. Hann,M.M. and Oprea,T.I. (2004) Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol., 8, 255-263.
8. Lee,K.W. et al. (2007) Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis, 28, 1918-1927.
9. Lu,J. et al. (2006) Inhibition of Mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. Cancer Res., 66, 4410-4418.
10. Macarron,R. (2006) Critical review of the role of HTS in drug discovery. Drug Discov. Today, 11, 277-279.
11. Marshall,G.R. (1987) Computer-aided drug design. Annu. Rev. Pharmacol. Toxicol., 27, 193-213.
12. McGovern,S.L. et al. (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem., 45, 1712-1722.
13. Mestres,J. et al. (2008) Data completeness-the Achilles heel of drug-target networks. Nat. Biotechnol., 26, 983-984.
14. Riggs,T.L. (2004) Research and development costs for drugs. Lancet 363, 184.
15. Ryan,A.J. et al. (2003) Effect of detergent on 'promiscuous' inhibitors. J. Med. Chem., 46, 3448-3451.
16. Seidler,J. et al. (2003) Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477-4486.
17. von Moltke,L.L. et al. (2004) Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 56, 1039-1044.
18. Whitebread,S. et al. (2005) Keynote review: in vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Discov. Today, 10, 1421-1433.
19. Wu,D. et al. (2008) D-Alanine:D-alanine ligase as a new target for the flavonoids quercetin and apigenin. Int. J. Antimicrob. Agents, 32, 421-426.
20. Zerhouni,E. (2003) Medicine. The NIH Roadmap. Science, 302, 63-72.